<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141338">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261000</url>
  </required_header>
  <id_info>
    <org_study_id>23051</org_study_id>
    <secondary_id>WS921563</secondary_id>
    <nct_id>NCT01261000</nct_id>
  </id_info>
  <brief_title>Tissue Biomarker for Pegvisomant Action</brief_title>
  <official_title>Tissue Biomarker for Pegvisomant Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acromegaly is a disease of the pituitary gland that involves the overproduction of growth
      hormone. The drug works by blocking the binding of growth hormone to growth hormone
      receptors found in tissues throughout the body. Human studies have evaluated the reduction
      of IGF-I levels in the blood following pegvisomant treatment, however, no studies have
      evaluated IGF-I levels in tissues following pegvisomant administration. In this study, we
      will test a novel tissue biomarker for pegvisomant action, distinct from measuring IGF-I
      levels in the blood. To this end, we will determine if administration of pegvisomant
      modifies the expression of IGF-I, IGF-I receptor, growth hormone receptor and GH- and
      IGF-i-dependent signaling molecules in the colon tissue of patients with acromegaly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Develop a tissue biomarker for pegvisomant action, other than serum IGF-I</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Pegvisomant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvisomant</intervention_name>
    <description>Pegvisomant used as indicated</description>
    <arm_group_label>Pegvisomant</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has provided written informed consent prior to any study related
             procedure

          -  The patient age is between 18 and 80 years inclusive

          -  The patient is male or female. If the woman is at risk of becoming pregnant, she must
             agree to use an effective method of contraception including implants, injectables,
             combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomo Melmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 2, 2015</lastchanged_date>
  <firstreceived_date>December 15, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Shlomo Melmed, MD</investigator_full_name>
    <investigator_title>Senior Vice President, Academic Affairs</investigator_title>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
